Abstracts tagged "methotrexate (MTX)"

Abstract Number: 499 • 2012 ACR/ARHP Annual Meeting
What Is the Right Dose to Start Methotrexate (7.5 or 15mg) in Rheumatoid Arthritis? (A Randomized Controlled Trial)
Varun Dhir¹, Mandeep Singla², Palvi Goyal², Vinay Sagar², Aman Sharma¹ and Shefali K. Sharma², ¹Internal Medicine (Rheumatology Unit), Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²Internal Medicine (Rheumatology Unit), Post Graduate Institute of Medical Education and Research, Chandigarh, India
Background/Purpose: Recent recommendations have suggested higher starting doses of methotrexate, i.e. 15 mg/week (3E initiative) in rheumatoid arthritis. However, studies comparing conventional (7.5mg) and newer…
Abstract Number: 2074 • 2012 ACR/ARHP Annual Meeting
Combined Effects of a c-Fos/AP-1 Inhibitor T-5224 and Methotrexate On Collagen-Induced Arthritis in Mice
Tomomi Date¹, Yukihiko Aikawa¹, Tetsuya Yamamoto¹, Hirokazu Narita¹, Shuichi Hirono² and Shunichi Shiozawa³, ¹Research Laboratories, Toyama Chemical Co., Ltd, Toyama, Japan, ²Department of Pharmaceutical Sciences, School of Pharmacy, Kitasato University, Tokyo, Japan, ³Department of Medicine & Rheumatology, Kyushu University Beppu Hospital, Beppu, Japan
Background/Purpose: Activator protein-1 (AP-1) is an important transcription factor for cytokine production and joint destruction in rheumatoid arthritis (RA), and a potential target for the…
Abstract Number: 455 • 2012 ACR/ARHP Annual Meeting
Lack of Additive Benefits of Concomitant Methotrexate Use to Tocilizumab Monotherapy for Rheumatoid Arthritis in Daily Clinical Practice
Keisuke Izumi¹, Yuko Kaneko², Hidekata Yasuoka³, Noriyuki Seta⁴, Hideto Kameda⁵, Masataka Kuwana⁵ and Tsutomu Takeuchi⁶, ¹Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan, ²Dept of Internal Medicine, Keio Univ School of Medicine, Shinjuku-ku, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio Univ School of Medicine, Tokyo, Japan, ⁴Department of Internal Medicine, Keio university, Tokyo, Japan, ⁵Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁶Keio University School of Medicine, Tokyo, Japan
Background/Purpose: To explore the benefit of concomitant use of methotrexate (MTX) for the effectiveness of TCZ in rheumatoid arthritis (RA) patients in daily clinical practice.…
Abstract Number: 1849 • 2012 ACR/ARHP Annual Meeting
Value of Matrices Developed to Identify Early Rheumatoid Arthritis Patients with Rapid Radiographic Progression Despite Methotrexate Therapy: A Comparison of Their Performance in the Early Rheumatoid Arthritis Espoir Cohort
Bruno Fautrel¹, Benjamin Granger², Bernard Combe³, Francis Guillemin⁴, Alain Saraux⁵ and Xavier Le Loët⁶, ¹Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, ²Biostatistics - GRC08-EEMOIS, Université Pierre et Marie Curie - Paris 6 ; AP-HP, Paris, France, ³CHU Lapeyronie, Montpellier, France, ⁴Hopitaux de Brabois, Nancy, France, ⁵Department of rheumatology and unit of immunology (EA 2216), Université Brest Occidentale, Brest, France, ⁶Rheumatology, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France
Background/Purpose: Rapid radiographic progression (RRP) – i.e., increase of the Sharp/van der Heijde score (vSHS) ≥ 5 points during the 1st year – is a…
Abstract Number: 398 • 2012 ACR/ARHP Annual Meeting
Basal Metabolic Rate As an Indicator of Rheumatoid Arthritis Disease Activity and Predictor of Remission
Heather Jones¹, Annette Szumski² and Andrew S. Koenig³, ¹Pfizer Inc., Collegeville, PA, ²Specialty Care, Pfizer Inc., Collegeville, PA, ³Specialty Care Business Unit, Pfizer Inc., Collegeville, PA
Background/Purpose: The role of body mass index (BMI) in rheumatoid arthritis (RA) disease activity and response to treatment has been difficult to determine.1 As a…
Abstract Number: 1822 • 2012 ACR/ARHP Annual Meeting
Liver Toxicity Monitoring and Its Impact On Methotrexate Discontinuation in a National Cohort of Veterans
Gabriela Schmajuk¹, Yinghui Miao², Jinoos Yazdany³, Mary Margaretten⁴ and Michael Steinman², ¹Rheumatology, UCSF / San Francisco VA Medical Center, San Francisco, CA, ²Division of Geriatrics, UCSF, San Francisco Veterans Affairs Medical Center, San Francisco, CA, ³Medicine, University of California, San Francisco, San Francisco, CA, ⁴Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: The National Quality Forum recently endorsed a controversial quality measure that assesses liver toxicity monitoring for patients receiving oral methotrexate (MTX). Using national data…
Abstract Number: 352 • 2012 ACR/ARHP Annual Meeting
Meta-Analysis: Influence of Methotrexate, Anti-TNF and Rituximab On the Immune Response to Influenza and Pneumococcal Vaccines in Patients with Rheumatoïd Arthritis
Charlotte Hua¹, Thomas Barnetche², Bernard Combe³ and Jacques Morel⁴, ¹Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ²Rheumatology, CHU Bordeaux Pellegrin, Bordeaux, France, ³Rheumatology, Hopital Lapeyronie, Montpellier, France, ⁴Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France
Background/Purpose: Vaccines against influenza and streptococcus pneumonia are currently recommended for patients with rheumatoid arthritis (RA). This meta-analysis assesses current literature data on the impact…
Abstract Number: 1827 • 2012 ACR/ARHP Annual Meeting
Factors That Impact Work Productivity in the Preserve Trial: A Randomized Controlled Trial of Combination Etanercept-Methotrexate Therapy in Patients with Moderately Active Rheumatoid Arthritis
Vibeke Strand¹, Thomas V. Jones², Wenzhi Li³, Andrew S. Koenig⁴ and Sameer Kotak⁵, ¹Adjunct, Division of Immunology / Rheumatology, Stanford University, Portola Valley, CA, ²Inflammation Specialty Care, Pfizer, Inc, Collegeville, PA, ³Pfizer Inc., Collegeville, PA, ⁴Specialty Care Business Unit, Pfizer Inc., Collegeville, PA, ⁵Specialty Care, Pfizer Inc., New York, NY
Background/Purpose: Active joint inflammation and structural damage in patients with rheumatoid arthritis (RA) often result in impaired physical function and ultimately work disability.1,2 Lost productivity…
Abstract Number: 354 • 2012 ACR/ARHP Annual Meeting
Delayed Onset of Hepatitis and/or Neutropenia in Patients with Rheumatoid Arthritis Treated with Combination Therapy of Methotrexate and Leflunomide
Seung Won Choi¹, Ji Seon Oh¹, You Jae Kim², Bon San Koo², Min Wook So², Yong-Gil Kim², Chang-Keun Lee² and Bin Yoo², ¹Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, South Korea, ²Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea
Background/Purpose: The adverse effects of combination therapy of methotrexate (MTX) and leflunomide (LEF) have been reported in many studies. Because combination of various doses of…
Abstract Number: 1719 • 2012 ACR/ARHP Annual Meeting
What Do Patients Put up with for the Benefit They Get From Methotrexate?
Sandra M. Robinson¹, Peta S. Heslop¹ and David Walker², ¹R&D, North Tyneside General Hospital, North Shields, United Kingdom, ²Dept of Rheumatology, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
Background/Purpose: As with all effective drugs, Methotrexate (MTX) comes with a range of side effects. Some such as pneumonitis are severe enough to require the…
Abstract Number: 355 • 2012 ACR/ARHP Annual Meeting
Metaanalysis of 5-Aminoimidazole-4-Carboxamide Ribonucleotide Transformylase (ATIC) 347C>G Polymorphism Affecting Methotrexate Efficacy and Toxicity in Rheumatoid Arthritis Patients
Fardina Malik¹ and Prabha Ranganathan², ¹Internal Medicine, Alton Memorial Hospital, Alton, IL, ²Div of Rheumatology, Washington Univ School of Med, St. Louis, MO
Background/Purpose: Methotrexate (MTX) exerts its effect in part by inhibiting 5-aminoimidazole-4-carboxamide ribonucleotide transformylase (ATIC), a key enzyme in the purine biosynthetic pathway. Published data suggests…
Abstract Number: 1722 • 2012 ACR/ARHP Annual Meeting
Exploring How Patients with Rheumatoid Arthritis Use a Methotrexate Decision Aid for Making Treatment Choices
Linda C. Li¹, Anne F. Townsend², Paul M. Adam³, Catherine L. Backman⁴, Sydney Brooks⁵, Gwen A. Ellert⁶, Allyson Jones⁷, Otto Kamensek⁸, Cheryl Koehn⁹, Diane Lacaille⁸, Jenny Leese², Colleen Maloney⁸, Elaine Yacyshyn¹⁰, Charlene Yousefi⁸ and Dawn Stacey¹¹, ¹Department of Physical Therapy, University of British Columbia, Vancouver, BC, Canada, ²Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, ³Rheumatology Liaison, Mary Pack Arthritis Centre, Vancouver, BC, Canada, ⁴Occupational Science & Occupational Therapy, The University of British Columbia, Vancouver, BC, Canada, ⁵The Arthritis Society, Ontario Division, Toronto, ON, Canada, ⁶Health Education, Trelle Enterprises Inc, Vancouver, BC, Canada, ⁷Department of Physical Therapy, University of Alberta, Edmonton, AB, Canada, ⁸Arthritis Research Centre of Canada, Vancouver, BC, Canada, ⁹Arthritis Consumer Experts, Vancouver, BC, Canada, ¹⁰562 Heritage Med Rsch Ctr, University of Alberta, Edmonton, AB, Canada, ¹¹School of Nursing, University of Ottawa, Ottawa, ON, Canada
Background/Purpose: For patients with rheumatoid arthritis (RA), making treatment decisions can be overwhelming. The literature describes a sense of ambivalence among patients with chronic diseases…
Abstract Number: 357 • 2012 ACR/ARHP Annual Meeting
Is the Impact of Methotrexate On Mortality in Rheumatoid Arthritis Independent of Its Effect On Disease Activity?
Dietmar MJ Krause¹, Bernadette Gabriel², Gertraud Herborn³ and Rolf Rau⁴, ¹Internistische und rheumatologische Gemeinschaftspraxis, Gladbeck, Germany, ²Private Practice, Gladbeck, Germany, ³Rheumatology, Evangelisches Fachkrankenhaus, Ratingen, Germany, ⁴Evangelisches Fachkrankenhaus, Ratingen, Germany
Background/Purpose: Methotrexate (MTX) is the anchor drug in the treatment of rheumatoid arthritis (RA). MTX shows effects on disease activity, radiologic progression and mortality. These…
Abstract Number: 2582 • 2012 ACR/ARHP Annual Meeting
Bone Anabolic Changes Progress in Psa Patients Despite Treatment with Methotrexate or Tumour Necrosis Factor Inhibitors
Stephanie Finzel¹, Sebastian Kraus¹, Sarah Schmidt¹, Axel J. Hueber², Juergen Rech³, Klaus Engelke⁴, Matthias Englbrecht¹ and Georg Schett¹, ¹Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ³Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ⁴Institute of Medical Physics, University of Erlangen, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: To investigate whether methotrexate (MTX) or tumour necrosis factor inhibition (TNFi) affect osteophyte formation in patients with psoriatic arthritis (PsA). Methods: 41 patients with…
Abstract Number: 1653 • 2012 ACR/ARHP Annual Meeting
Outcomes in Patients with Granulomatosis with Polyangiitis (Wegener’s) Treated with Short- Vs. Long-Term Maintenance Therapy
Jason Springer¹, Benjamin Nutter², Carol A. Langford³, Gary S. Hoffman⁴ and Alexandra Villa-Forte⁵, ¹Dept of Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, ²Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH, ³Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ⁴Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ⁵Rheumatology, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Disease remission can be successfully achieved in the majority of patients (pts) with Granulomatosis with polyangiitis (Wegener’s) (GPA). After remission (rem) is achieved continued…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].